Topic:

M&A

Latest Headlines

Latest Headlines

Valeant makes offer for Zoetis, sources tell WSJ

Rapidly expanding Valeant has approached Zoetis about a buyout, sources told the Wall Street Journal. Rumors of a possible deal, which have been bouncing back and forth for weeks, set off buying, with Zoetis shares closing up 11% Thursday at an all-time high of $55.38.

Allergan CEO: 'The cuts are done' at layoffs-plagued Irvine campus

The good news for Allergan's ex-headquarters in Irvine, CA: CEO Brent Saunders says the operations there are still key to the company. More good news: The layoffs that hit that site are now over and done, he says.

CAR-T's explosion puts Juno and Kite under the M&A spotlight

The promise of new treatments that use the body's own immune cells to fight cancer has sent soaring the value of a handful of biotech startups, and analysts say Big Pharma may be waiting in the wings with buyout offers as the science continues to progress.

Generics maker Alvogen eyes faster growth after CVC-led buyout

A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in a deal valuing Alvogen at $2 billion.

Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit

Patterson Companies, a Minnesota-based production and animal health distribution company, completed its $1.1 billion acquisition of Animal Health International in a deal that doubles the size of the company's veterinary unit.

Teva ratchets up its M&A pressure on Mylan with larger stake

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

Medtronic buys noninvasive 3-D cardiac mapping startup CardioInsight for $100M+

Undisputed medical device heavyweight Medtronic has been busily wheeling and dealing with tiny startups this year--perhaps putting to rest industry concern that the merger with Covidien would put a damper on strategic backing for private med tech companies as a key player was eliminated.

Teva turns up the heat on Mylan, taking its stake past critical threshold

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

Synergy's clinical success fuels the M&A rumor mill

A Phase III victory for Synergy Pharmaceuticals' constipation drug has made the company an attractive takeout target, analysts say, with the acquisitive Valeant Pharmaceuticals a potential suitor.

After 2014 IPO and recent takeover rumor, medical laser player Lumenis to be acquired for $510M

XIO Group will buy Israeli medical laser player Lumenis for about $510 million in cash. That price tag isn't much of a premium to the company's valuation because a rumor that it would be acquired for about $500 million by China's Fosun Pharma already pushed shares up earlier this year.